After announcing cooperation, Kazia Therapeutics Limited (NASD: KZIA) is climbing the charts today, up 7.29% to trade at $0.5901 at the last check.
Top 5 Tech Stocks to Buy in 2024
Don't let the chaos of rising interest rates, potential recession, tighter credit issues, higher oil prices, and incessant geopolitical issues chase you from the markets. Instead, just wait it out. With too much fear in the market, go bargain hunting with tech stocks. We have complied a report with the five of the best ways to profit within this industry.
"Top 5 AI Stocks to Buy in 2024."
Click here to sign up for our free report & newsletter, plus bonus offer "Elon Musk just Tiggered a BOOM in These Stocks"
Sponsored
Who will KZIA be cooperating with?
In order to investigate cutting-edge applications of paxalisib in solid tumors, Kazia Therapeutics (KZIA) has partnered with QIMR Berghofer Medical Research Institute, one of Australia’s premier cancer research institutions.
PI3K/mTOR inhibitor paxalisib, the company’s flagship asset, is a target for Kazia Therapeutics’ research in solid tumors. The research cooperation intends to expand on earlier work, including the potential application of paxalisib as an immunological moderator in solid malignancies. The continued partnership will expand on earlier studies, such as the application of paxalisib as an immune modulator in the treatment of disorders like breast cancer, which has already resulted in the submission of a patent.
The study creates a significant prospect for paxalisib to be used in conjunction with Keytruda and Opdivo to treat conditions including breast cancer and lung cancer. Such combinations may be able to enhance patient outcomes if they are successful in clinical studies. Following the recent setback in the GBM AGILE study where paxalisib was unable to graduate to stage 2 of the Phase III trial, KZIA recently announced inspiring statistics in an investigational melanoma study, outlining its growing focus on uncovering indications other than brain cancer and brain metastases.
The study findings are scheduled to be published in 1H CY2023, and conversations about potential translation to clinical trials in CY2023 are still continuing. Upon confirmation, it may open the door to the use of paxalisib in conjunction with checkpoint inhibitors like Keytruda and Opdivo for the treatment of solid malignancies including breast and lung cancer.
How will KZIA make use of the results?
Initial in-vitro results showed paxalisib to demonstrate suppression of both the original tumor and metastasis by enhancing the immune response inside the tumor microenvironment, which encouraged Kazia Therapeutics (KZIA). Instead of KZIA’s usual emphasis on brain malignancies, the partnership may be a start toward investigating the applicability of paxalisib in additional cancer indications.
